Newborn children with HCM should be treated following standard hypertrophic cardiomyopathy guidelines. Although treatment is standard, neonatal patients with Noonan Syndrome have a higher risk of ...

Genetic testing can help to confirm a patient's diagnosis, as well as identify family members who may also be affected so that interventions can be started as soon as possible Hypertrophic ...

As Fady will elaborate, the additional analyses show that treatment with aficamten ... European Society of Cardiology Congress, the Hypertrophic Cardiomyopathy Society Scientific Sessions and ...

Stay up to date on the latest science and guidelines ... most recent science and clinical guidance for treatment of atrial fibrillation, including the role of antiarrhythmic drugs (AADs). Hypertrophic ...

BACKGROUND: Patients with hypertrophic cardiomyopathy without left ventricular outflow tract obstruction commonly experience ...

A study has found that aficamten is associated with improvements across a range of clinical outcomes in patients with obstructive hypertrophic cardiomyopathy.

HCM is a relatively common genetic cardiomyopathy that can be a challenge to diagnose, with about one in three patients misdiagnosed as having another cardiomyopathy. Genetic testing identifies a ...

Opens in a new tab or window A small panel of circulating biomarkers may reliably distinguish hypertrophic cardiomyopathy (HCM) from similar conditions that cause left ventricular hypertrophy (LVH ...

Background: Symptoms are among the most important factors impacting quality of life (QOL) in hypertrophic cardiomyopathy (HCM) patients, and reflect a poor prognosis. Whether emotional stress can ...

Hypertrophic cardiomyopathy (HCM ... and the most appropriate investigations for persons suspected of having HCM. Treatment strategies for the disease and its complications are presented briefly.

Death is a daunting prospect for many, but after a lot of reflection and work on herself, Bella Salsberry feels at peace with the life she's been granted.

BACKGROUND: The ability to predict recovery of left ventricular ejection fraction (LVEF) in response to guideline-directed therapy among patients with nonischemic cardiomyopathy is desired. We sought ...